Rhinomed Limited (ASX:RNO) is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information, go to www.rhinomed.global
Follow the Turbine on Twitter at @theturbinecom
Follow Mute Snoring on Twitter at @mutesnoring
Rhinomed Ltd (ASX:RNO) is encouraged by the strong level of interest in the technology platform from customers and partners both within Australian and overseas. The company is in a strong financial position to take full advantage of the technology platform that has been created over the last 18 months.
Rhinomed Ltd (ASX:RNO) is pleased to announce that it will begin shipping its next generation Turbine technology on February 9th, 2015.
Rhinomed develops, markets and partners it's internal nasal technology platform into multiple form factors - internal nasal devices, with a focus on unmet needs in sport & exercise, sleep (snoring, sleep quality and sleep apnea), wellness and drug delivery
Melbourne technology firm, Rhinomed (ASX:RNO) today announced that CEO and Managing Director Mr. Michael Johnson will present a company update at the 8th Annual OneMed Forum on Monday, 12th January 2015 at 11.40 PST at the Marriott Marquis in San Francisco.
Melbourne technology firm, Rhinomed (ASX:RNO) is pleased to announce that it has appointed sales and marketing brokerage firm Brand Solutions Australia to represent Mute in the Australian Pharmacy and Grocery channel.
Melbourne technology firm, Rhinomed (ASX:RNO) is pleased to announce that it has received a Research and Development tax refund of $570,337.
Melbourne bio-technology firm, Rhinomed (ASX:RNO) is pleased to announce the release of its newest device from its nasal respiratory technology stable of products, Mute(TM), a nasal breathing aid to alleviate snoring and improve sleep quality.
Melbourne technology firm, Rhinomed (ASX:RNO) is pleased to announce that it has successfully completed the testing and technical documentation that has enabled its new novel snoring and sleep quality product - Mute(TM) to gain acceptance with the US Food and Drug Administration(FDA), European authority (CE Mark) and the Australian Therapeutic Goods Association (TGA).
Melbourne technology firm, Rhinomed (ASX:RNO) today announced the topline results from its independent trial in snoring, sleep quality and night time nasal congestion which successfully demonstrated significant benefit of its new Mute nasal technology. The Company has submitted applications to the European, US and Australian regulatory authorities that will allow sale of the Mute technology to commence.
Medical technology company Rhinomed Limited (ASX:RNO) is pleased to announce that it has successfully completed the testing and technical documentation that has enabled its sport technology the Turbine(TM) to receive the CE Mark.
